2.87
price up icon0.70%   0.02
after-market After Hours: 2.90 0.03 +1.05%
loading
Aquestive Therapeutics Inc stock is traded at $2.87, with a volume of 668.86K. It is up +0.70% in the last 24 hours and down -10.87% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$2.85
Open:
$2.82
24h Volume:
668.86K
Relative Volume:
0.45
Market Cap:
$255.09M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-7.8824
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
+14.34%
1M Performance:
-10.87%
6M Performance:
-47.72%
1Y Performance:
-26.97%
1-Day Range:
Value
$2.79
$2.895
1-Week Range:
Value
$2.465
$2.97
52-Week Range:
Value
$2.20
$5.80

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name
Name
Aquestive Therapeutics Inc
Name
Phone
908-941-1900
Name
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Name
Employee
142
Name
Twitter
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
AQST's Discussions on Twitter

Compare AQST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AQST
Aquestive Therapeutics Inc
2.87 255.09M 58.36M -25.72M -24.91M -0.3641
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.47 65.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 46.99B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.18 45.96B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
14.87 17.04B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
291.38 12.77B 2.76B 1.11B 898.10M 22.77

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-17-24 Initiated Cantor Fitzgerald Overweight
May-10-24 Initiated Leerink Partners Outperform
Apr-11-24 Initiated Piper Sandler Overweight
Mar-28-24 Initiated Raymond James Outperform
Apr-07-21 Resumed RBC Capital Mkts Outperform
Apr-22-19 Initiated H.C. Wainwright Buy
Jan-03-19 Initiated Lake Street Buy
Aug-20-18 Initiated JMP Securities Mkt Outperform
Aug-20-18 Initiated RBC Capital Mkts Outperform
View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

pulisher
Apr 26, 2025

The 14% return this week takes Aquestive Therapeutics' (NASDAQ:AQST) shareholders three-year gains to 105% - simplywall.st

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Trims Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

Russell Investments Group Ltd. Has $386,000 Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Check out these key findings about Aquestive Therapeutics Inc (AQST) - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Recent Insider Activity Suggests Potential Gains for Aquestive Therapeutics Inc (AQST) - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Strong at 2.58, Up 2.79 - DWinneX

Apr 22, 2025
pulisher
Apr 21, 2025

Does Aquestive Therapeutics Inc (NASDAQ: AQST) Still Need To Convince Analysts? - Stocksregister

Apr 21, 2025
pulisher
Apr 18, 2025

Vanguard Group Inc. Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

Raymond James Financial Inc. Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat

Apr 11, 2025
pulisher
Apr 09, 2025

Aquestive completes marketing application for Anaphylm in U.S. - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - The Manila Times

Apr 09, 2025
pulisher
Apr 09, 2025

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewswire Inc.

Apr 09, 2025
pulisher
Apr 08, 2025

Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World

Apr 07, 2025
pulisher
Apr 04, 2025

HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com

Apr 03, 2025
pulisher
Apr 03, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Aquestive’s Anaphylm shows promise in pediatric study By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive’s Anaphylm shows promise in pediatric study - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Aquestive Therapeutics Announces Positive Topline PK Results From Its Pediatric Study And Completes The NDA Submission For Anaphylm™ (Epinephrine) Sublingual Film - MENAFN.com

Apr 01, 2025
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Aquestive stock falls amid Libervant approval, Anaphylm update - MSN

Mar 30, 2025
pulisher
Mar 27, 2025

Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Mar 27, 2025
pulisher
Mar 25, 2025

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha

Mar 25, 2025
pulisher
Mar 24, 2025

Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha

Mar 24, 2025
pulisher
Mar 21, 2025

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st

Mar 21, 2025
pulisher
Mar 12, 2025

What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025
pulisher
Mar 10, 2025

Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks

Mar 10, 2025

Aquestive Therapeutics Inc Stock (AQST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$9.46
price up icon 0.00%
$27.84
price up icon 0.61%
$101.77
price down icon 1.80%
$8.13
price up icon 1.25%
$106.73
price up icon 0.92%
$291.38
price down icon 1.70%
Cap:     |  Volume (24h):